What is Repligen's investment proceeds?

Repligen (RGEN) reported investment proceeds of $66M in Q1 2026.

What does investment proceeds mean?

Cash received from sales, maturities, and redemptions of investment securities across all categories.

Repligen RGEN Investment Proceeds

Investment Proceeds at other companies

TEC

Bio-TechneTECH

$1.09M-95.4%

DanaherDHR

$0-100%

Bio-Rad LaboratoriesBIO

$145.1M-15.2%

STERISSTE

$0—

Arrowhead ResearchARWR

$115.34M-2.4%

Other financials

Income statement

See full

Revenue$194.3M+14.8%

Gross profit$108.3M+18.5%

Operating income$15.9M+142%

Net income$8.3M+42.9%

EPS (diluted)$0.15+50.0%

Balance sheet

See full

Cash & equivalents$582.7M-16.4%

Total debt$687.6M+346%

Total equity$2.1B+6.0%

Total assets$2.9B+2.8%

Cash flow

See full

Operating cash flow$28.3M+88.6%

CapEx$4.7M+32.2%

Free cash flow$23.6M+106%

Valuation

See full

Market cap$7.45B-7.1%

Enterprise value$7.55B+2.1%

P/E144.9×—

P/S10.1×-0.1×

Profitability

See full

Gross margin49.5%+2.7pp

Operating margin1.5%-14.0pp

Net margin17.1%-3.7pp

FCF margin21.2%+6.1pp

Returns & leverage

See full

Return on equity2.5%+1.9pp

Debt / equity0.3×+0.2×

Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Repligen's investment proceeds?: Repligen (RGEN) reported investment proceeds of $66M in Q1 2026.
What does investment proceeds mean?: Cash received from sales, maturities, and redemptions of investment securities across all categories.